Experts speculate on why Eli Lilly's Alzheimer's drug failed

08/17/2010 | Forbes

The recent halt of a study involving Eli Lilly's experimental Alzheimer's disease drug, a compound known as a gamma secretase inhibitor, has some experts speculating on what could have went wrong with the drug. The drug was designed to target the brain's amyloid protein, which is thought to accelerate the development of the disease. One angle being considered is that amyloid is really an effect of the disease, not its cause, and targeting it could make the disease worse.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY
Director of Payor/Provider Contracting
U.S. Medical Management
Tryo, MI